SlowBull
The Business Brief MONDAY, 17 AUGUST 2026
← All stories
Markets

EyePoint plummets on pivotal data for main drug

1 source ·1 article ·3h ago

Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·3h ago

EyePoint plummets on pivotal data for main drug

Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.